Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

DT120 ODT Receives Second FDA Breakthrough Therapy Designation in MDD

8 September 2026 · By · Wire by Fusion42

Published

8 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at hcplive.com →

◆ Verified

Fusion42 · 9 September 2026 · Fusion42 review

DT120 ODT has received a second Breakthrough Therapy Designation from the FDA for the treatment of major depressive disorder (MDD), highlighting its potential as a significant advancement in depression therapeutics.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You can capitalise on faster FDA review pathways as DT120 ODT sets precedence for breakthrough status in depression drugs. This regulatory nod opens routes to accelerate your therapy development and raise investor interest.

◆ Coverage

1 source · 8 Sep 2026

◆ Related on Wire

◆ Topics

Biotechfdabreakthrough-therapydepressionmajor-depressive-disorderdrug-development